Perspectives on the value of biomarkers in acute cardiac care and implications for strategic management

Biomarker Insights

Volumn 8, Issue , 2013, Pages 115-126

  Kossaify, Antoine ^a   Garcia, Annie ^a   Succar, Sami ^a   Ibrahim, Antoine ^a   Moussallem, Nicolas ^a   Kossaify, Mikhael ^b   Grollier, Gilles ^b  

^a HOLY SPIRIT UNIVERSITY OF KASLIK USEK   (Lebanon)

^b CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Acute cardiac care; Assays; Biomarker; Management; Point of care

Indexed keywords

AMMONIA; C REACTIVE PROTEIN; CD40 LIGAND; CHROMOGRANIN A; FATTY ACID BINDING PROTEIN; INTERLEUKIN 6; LACTIC ACID; MATRIX METALLOPROTEINASE; NATRIURETIC FACTOR; TROPONIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ACUTE HEART INFARCTION; AMMONIA BLOOD LEVEL; ARTICLE; CLINICAL ASSESSMENT; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DYSPNEA; ENDOTHELIAL DYSFUNCTION; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART SURGERY; HUMAN; HYPERTENSIVE CRISIS; INFLAMMATION; LACTATE BLOOD LEVEL; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT CARE; POINT OF CARE TESTING; PROGNOSIS; THORAX PAIN;

EID: 84883614472     PISSN: 11772719     EISSN: None     Source Type: Journal    
DOI: 10.4137/BMI.S12703     Document Type: Article

References (110)

1. Vivanco F, Padial LR, Darde VM, et al. Proteomic Biomarkers of Atherosclerosis. Biomark Insights. 2008;3:101-113.
2. Singh V, Martinezclark P, Pascual M, Shaw ES, O'Neill WW. Cardiac biomarkers-the old and the new: a review. Coron Artery Dis. 2010;21(4): 244-256.
3. McLean AS, Huang SJ. Cardiac biomarkers in the intensive care unit. Ann Intensive Care. 2012;2:8.
4. Chan MY, Andreotti F, Becker RC. Hypercoagulable states in cardiovascular disease. Circulation. 2008;118(22):2286-2297.
5. Loria V, Leo M, Biasillo G, Dato I, Biasucci LM. Biomarkers in Acute Coronary Syndrome. Biomark Insights. 2008;3:453-468.
6. Aldous SJ. Cardiac biomarkers in acute myocardial infarction. Int J Cardiol. 2013;164(3):282-294.
7. Thygesen K, Mair J, Mueller C, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J. 2012;33(16):2001-2006.
8. Levin ER, Gardner DG, Samson WK. Natriuretic Peptides. N Engl J Med. 1998;339(5):321-328.
9. Hammerer-Lercher A, Halfnger B, Sarg B, et al. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem. 2008;54(5):858-865.
10. Palmer CS, Yandle TG, Nicholls G, Frampton CM, Richards AM. Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma. Eur J Heart Fail. 2009;11(9):832-839.
11. Mair J, Falkensammer G, Pölzl G, Hammerer-Lercher A, Griesmacher A, Pachinger O. B-type natriuretic peptide (BNP) is more sensitive to rapid hemodynamic changes in acute heart failure than NT-proBNP. Clin Chim Acta. 2007;379(1-2):163-166.
12. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343(8895):440-444.
13. Zaninotto M, Mion MM, Di Serio F, Caputo M, Ottomano C, Plebani M. PATH-FAST NT-proBNP (N-terminal-pro B type natriuretic peptide): a multicenter evaluation of a new point-of-care assay. Clin Chem Lab Med. 2010;48(7):1029-1034.
14. Ishii J. Clinical utility of NT-proBNP, a new biomarker of cardiac function and heart failure. Rinsho Byori. 2008;56(4):316-321.
15. Ridker PM. High-sensitivity C-reactive protein, infammation, and cardiovascular risk: from concept to clinical practice to clinical beneft. Am Heart J. 2004;148(Suppl 1):S19-S26.
16. Kraus VB, Jordan JM. Serum C-Reactive Protein (CRP), Target for Therapy or Trouble? Biomark Insights. 2007;1:77-80.
17. Meier-Ewert HK, Ridker PM, Rifai N, et al. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem. 2001;47(3):426-430.
18. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem. 2004;279(47):48487-4890.
19. Dietrich M, Jialal I. The effect of weight loss on a stable biomarker of infammation, C-reactive protein. Nutr Rev. 2005;63(1):22-28.
20. Verma S. C-reactive protein incites atherosclerosis. Can J Cardiol. 2004;20 Suppl B:29B-31B.
21. Pearson TA, Mensah GA, Alexander RW, et al. Markers of infammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511.
22. Wang F, Pan W, Pan S, Wang S, Ge Q, Ge J. Usefulness of N-terminal pro-brain natriuretic peptide and C-reactive protein to predict ICU mortality in unselected medical ICU patients: a prospective, observational study. Crit Care. 2011;15(1):R42.
23. Al-Hadi HA, Fox KA. Cardiac markers in the early diagnosis and management of patients with acute coronary syndrome. Sultan Qaboos Univ Med J. 2009;9(3):231-246.
24. Seo H, Miyazaki S, Furuno T, Nonogi H, Haze K, Hiramori K. Creatine kinase-MB protein mass is a better indicator for the assessment of acute myocardial infarction in the lower range of creatine kinase level. Jpn Heart J. 1993;34(6):717-727.
25. Penttilä I, Penttilä K, Rantanen T. Laboratory diagnosis of patients with acute chest pain. Clin Chem Lab Med. Mar 2000;38(3):187-97.
26. Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J. 2012;33(18):2252-2257.
27. Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J. 2010;31: 2197-2204.
28. Zaninotto M, Mion MM, Novello E, et al. Precision performance at low levels and 99th percentile concentration of the Access AccuTnI assay on two different platforms. Clin Chem Lab Med. 2009;47(3):367-371.
29. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Eng J Med. 2009;361: 858-867.
30. Giannitsis E, Katus HA. Comparison of cardiac troponin T and troponin I assays-implications of analytical and biochemical differences on clinical performance. Clin Lab. 2004;50(9-10):521-528.
31. Wu AH. A comparison of cardiac troponin T and cardiac troponin I in patients with acute coronary syndromes. Coron Artery Dis. 1999;10(2):69-74.
32. Capolaghi B, Charbonnier B, Dumontet M, et al. Prescription, assay and interpretation of cardiac troponins tests: guidelines from SFBC-CNBC troponin working group. Ann Biol Clin (Paris). 2005;63(3):245-261.
33. Fromm RE Jr. Cardiac troponins in the intensive care unit: common causes of increased levels and interpretation. Crit Care Med. 2007;35(2):584-588.
34. Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary vs. non-coronary disease. Eur Heart J. 2011;32(4):404-411.
35. Reynolds T, Cecconi M, Collinson P, Rhodes A, Grounds RM, Hamilton MA. Raised serum cardiac troponin I concentrations predict hospital mortality in intensive care unit patients. Br J Anaesth. 2012;109(2):219-224.
36. Agzew Y. Elevated serum cardiac troponin in non-acute coronary syndrome. Clin Cardiol. 2009;32(1):15-20.
37. Stein R, Gupta B, Agarwal S, et al. Prognostic implications of normal (,0.10 ng/mL) and borderline (0.10 to 1.49 ng/mL) troponin elevation levels in critically ill patients without acute coronary syndrome. Am J Cardiol. 2008;102(5):z509-z512.
38. Shah KB, Kop WJ, Christenson RH, et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem. 2011;57(6):874-882.
39. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem. 2010;43(9): 714-719.
40. Gori CS, Magrini L, Travaglino F, Di Somma S. Role of biomarkers in patients with dyspnea. Eur Rev Med Pharmacol Sci. 2011;15(2):229-240.
41. Cinar O, Cevik E, Acar A, et al. Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratifcation of dyspneic ED patients. Am J Emerg Med. 2012;30(9):1915-1520.
42. Maisel A, Mueller C, Nowak RM, et al. Midregion prohormone adrenom-edullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2011;58(10):1057-1067.
43. Dieplinger B, Gegenhuber A, Struck J, et al. Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure. Clin Chim Acta. 2009;400(1-2):91-96.
44. Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL Jr. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J. 2012;33:2197-2205.
45. Christ M, Popp S, Pohlmann H, et al. Implementation of high sensitivity cardiac troponin T measurement in the emergency department. Am J Med. 2010;123(12):1134-1142.
46. Collinson P, Goodacre S, Gaze D, Gray A; RATPAC Research Team. Very early diagnosis of chest pain by point-of-care testing: comparison of the diagnostic effciency of a panel of cardiac biomarkers compared with tro-ponin measurement alone in the RATPAC trial. Heart. 2012;98(4):312-318.
47. Collinson P, Gaze D, Thokala P, Goodacre S. Randomised Assessment of Treatment using Panel Assay of Cardiac markers-Contemporary Biomarker Evaluation (RATPAC CBE). Health Technol Assess. 2013;17(15):v-vi, 1-122.
48. Hlatky MA, Ashley E, Quertermous T, et al. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocar-dial infarction among patients with coronary artery disease. Am Heart J. 2007;154(6):1043-1051.
49. Tang QD, Wu PS, Hou YQ, et al. Plasma matrix metalloproteinases-2 and -9 levels are elevated in patients with acute coronary syndrome and coronary chronic total occlusion. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29:1004-1007.
50. Saenger AK, Beyrau R, Braun S, et al. Multicenter analytical evaluation of a high-sensitivity troponin T assay. Clin Chim Acta. 2011;412(9-10):748-754.
51. McMullin N, Lindsell CJ, Lei L, et al. Outcomes associated with small changes in normal-range cardiac markers. Am J Emerg Med. 2011;29(2):162-167.
52. Chew HC. Cardiac troponin T in acute coronary syndrome with renal insuffciency. Asian Cardiovasc Thorac Ann. 2008;16(4):284-287.
53. Moe KT, Wong P. Current trends in diagnostic biomarkers of acute coronary syndrome. Ann Acad Med Singapore. 2010;39(3):210-215.
54. Dekker MS, Mosterd A, van 't Hof AW, Hoes AW. Novel biochemical markers in suspected acute coronary syndrome: systematic review and critical appraisal. Heart. 2010;96(13):1001-1010.
55. Konstantino Y, Nguyen TT, Wolk R, Aiello RJ, Terra SG, Fryburg DA. Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease. Biomarkers. 2009;14(2):118-129.
56. Kobayashi N, Hata N, Kume N, et al. Matrix metalloproteinase-9 for the earliest stage acute coronary syndrome. Circ J. 2011;75(12):2853-2861.
57. Kim H, Yang DH, Park Y, et al. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J. 2006;70(11):1379-1384.
58. Hatmi ZN, Saeid AK, Broumand MA, Khoshkar SN, Danesh ZF. Multiple infammatory prognostic factors in acute coronary syndromes: a prospective inception cohort study. Acta Med Iran. 2010;48(1):51-57.
59. Gogo PB Jr, Schneider DJ, Terrien EF, Watkins MW, Sobel BE, Dauerman HL. Relation of leukocytosis to C-reactive protein and interleukin-6 among patients undergoing percutaneous coronary intervention. Am J Cardiol. 2005;96(4):538-542.
60. Schaan BD, Pellanda LC, Maciel PT, Duarte ER, Portal VL. C-reactive protein in acute coronary syndrome: association with 3-year outcomes. Braz J Med Biol Res. 2009;42(12):1236-1241.
61. Glaser R, Peacock WF, Wu AH, Muller R, Möckel M, Apple FS. Placental growth factor and B-type natriuretic peptide as independent predictors of risk from a multibiomarker panel in suspected acute coronary syndrome (Acute Risk and Related Outcomes Assessed With Cardiac Biomarkers [ARROW]) study. Am J Cardiol. 2011;107(6):821-826.
62. Karras DJ, Kane DL. Serum markers in the emergency department diagnosis of acute myocardial infarction. Emerg Med Clin North Am. 2001;19(2): 321-337.
63. Cojocaru M, Cojocaru IM, Silosi I. Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical infammation in cardiovascular diseases. Maedica (Buchar). 2010;5(1):51-55.
64. Möckel M, Müller R, Vollert J, et al. Lipoprotein-associated phospholipase A2 for early risk stratifcation in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol. 2007;96(9):604-612.
65. von Haehling S, Papassotiriou J, Hartmann O, et al. Mid-regional pro-atrial natriuretic peptide as a prognostic marker for all-cause mortality in patients with symptomatic coronary artery disease. Clin Sci (Lond). 2012;123(10): 601-610.
66. von Haehling S, Papassotiriou J, Morgenthaler NG, et al. Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease. Int J Cardiol. 2012;162(1):27-32.
67. Ataoǧlu HE, Yilmaz F, Uzunhasan I, Cetin F, Temiz L, Döventaş YE, et al. Procalcitonin: a novel cardiac marker with prognostic value in acute coronary syndrome. J Int Med Res. 2010;38(1):52-61.
68. Picariello C, Lazzeri C, Attanà P, Chiostri M, Gensini GF, Valente S. The impact of admission procalcitonin on prognosis in acute coronary syndromes: a pilot study. Biomarkers. 2012;17(1):56-61.
69. Guthikonda S, Haynes WG. Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep. 2006;8(2):100-106.
70. El Oudi M, Bouguerra C, Aouni Z, Mazigh C, Bellaaj R, Machghoul S. Homocysteine and infammatory biomarkers plasma levels, and severity of acute coronary syndrome. Ann Biol Clin (Paris). 2011;69(2):175-180.
71. Samimi-Fard S, Dominguez-Rodriguez A, Abreu-Gonzalez P, et al. Role of myeloperoxidase as predictor of systemic infammatory response syndrome in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol. 2009;104(5):634-637.
72. Roman RM, Camargo PV, Borges FK, Rossini AP, Polanczyk CA. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Coron Artery Dis. 2010;21(3): 129-136.
73. Dominguez-Rodriguez A, Samimi-Fard S, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and car-diogenic shock. Am J Cardiol. 2008;101(11):1537-1540.
74. Suzuki M, Hori S, Noma S, Kobayashi K. Prognostic value of a qualitative test for heart-type fatty acid-binding protein in patients with acute coronary syndrome. Int Heart J. 2005;46(4):601-606.
75. Ishii J, Ozaki Y, Lu J, et al. Prognostic value of serum concentration of heart-type fatty acid-binding protein relative to cardiac troponin T on admission in the early hours of acute coronary syndrome. Clin Chem. 2005;51(8): 1397-1404.
76. Danne O, Möckel M. Choline in acute coronary syndrome: an emerging biomarker with implications for the integrated assessment of plaque vulnerability. Expert Rev Mol Diagn. 2010;10(2):159-171.
77. Danne O, Möckel M, Lueders C, et al. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol. 2003;91(9):1060-7.
78. Ulus T, Yildirir A, Sade LE, et al. Serum gamma-glutamyl transferase activity: new high-risk criteria in acute coronary syndrome patients? Coron Artery Dis. 2008;19(7):489-495.
79. Dogan A, Icli A, Aksoy F, et al. Gamma-glutamyltransferase in acute coronary syndrome patients without ST elevation and its association with stenotic lesion and cardiac events. Coron Artery Dis. 2012;23(1):39-44.
80. Wilson AM, Ryan MC, Boyle AJ. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol. 2006;106(3): 291-297.
81. Alberto P, Francesca I, Chiara S, Ranuccio N. Acute coronary syndromes: from the laboratory markers to the coronary vessels. Biomark Insights. 2007;1:123-130.
82. Willoughby SR, Stewart S, Holmes AS, Chirkov YY, Horowitz JD. Platelet nitric oxide responsiveness: a novel prognostic marker in acute coronary syndromes. Arterioscler Thromb Vasc Biol. 2005;25(12):2661-2666.
83. Imamura T. Paradigm shift from myocardium-derived to plaque-derived biomarkers for very early diagnosis of acute myocardial infarction. Circ J. 2011;75(6):1322-3.
84. Kobayashi N, Hata N, Kume N, et al. Soluble lectin-like oxidized low-density lipoprotein receptor-1 as an early biomarker for ST elevation myocardial infarction: time-dependent comparison with other biomarkers. Circ J. 2011;75(6):1433-1439.
85. Di Stefano R, Di Bello V, Barsotti MC, et al. Infammatory markers and cardiac function in acute coronary syndrome: difference in ST-segment elevation myocardial infarction (STEMI) and in non-STEMI models. Biomed Pharmacother. 2009;63(10):773-780.
86. Figiel Ł, Wraga M, Bednarkiewicz Z, et al. Direct comparison of the diagnostic value of point-of-care tests detecting heart-type fatty acid binding protein or glycogen phosphorylase isoenzyme BB in patients with acute coronary syndromes with persistent ST-segment elevation. Kardiol Pol. 2011;69(1):1-6.
87. Cubranic Z, Madzar Z, Matijevic S, et al. Diagnostic accuracy of heart fatty acid binding protein (H-FABP) and glycogen phosphorylase isoenzyme BB (GPBB) in diagnosis of acute myocardial infarction in patients with acute coronary syndrome. Biochem Med (Zagreb). 2012;22(2):225-236.
88. Bozkurt S, Kaya EB, Okutucu S, Aytemir K, Coskun F, Oto A. The diagnostic and prognostic value of frst hour glycogen phosphorylase isoenzyme BB level in acute coronary syndrome. Cardiol J. 2011;18(5):496-502.
89. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003;42(4):728-735.
90. Desmoulin F, Galinier M, Trouillet C, et al. Metabonomics analysis of plasma reveals the lactate to cholesterol ratio as an independent prognostic factor of short-term mortality in acute heart failure. PLoS One. 2013;8:e60737.
91. Mebazaa A, Vanpoucke G, Thomas G, et al. Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identifcation of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur Heart J. 2012;33(18):2317-24.
92. Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. Mar 25, 2013. pii: S0167-5273(13)00288-X.
93. Visser M, Vermeulen MA, Richir MC, et al. Imbalance of arginine and asymmetric dimethylarginine is associated with markers of circulatory failure, organ failure and mortality in shock patients. Br J Nutr. 2012;107(10): 1458-65.
94. Vis MM, V d Schaaf RJ, Sjauw KD, et al. Creatinine clearance is independently associated with one year mortality in a primary PCI cohort with cardiogenic shock. Acute Card Care. 2009;11(2):107-112.
95. Picariello C, Lazzeri C, Chiostri M, Gensini G, Valente S. Procalcitonin in patients with acute coronary syndromes and cardiogenic shock submitted to percutaneous coronary intervention. Intern Emerg Med. 2009;4(5):403-408.
96. Thielmann M, Massoudy P, Neuhäuser M, et al. Prognostic value of preoperative cardiac troponin I in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. Chest. 2005;128(5):3526-3536.
97. Bertinchant JP, Ledermann B, Schmutz L, et al. Diagnostic and prognostic signifcance of CK-MB, troponins, CRP, BNP and/or NT-proBNP in coronary angioplasty. Elevation mechanisms and clinical implications. Arch Mal Coeur Vaiss. 2007;100(11):925-933.
98. Martínez-Dolz L, Almenar L, Reganon E, et al. What is the best biomarker for diagnosis of rejection in heart transplantation? Clin Transplant. 2009;23(5):672-680.
99. Shinozaki K, Oda S, Sadahiro T, et al. Blood ammonia and lactate levels on hospital arrival as a predictive biomarker in patients with out-of-hospital cardiac arrest. Resuscitation. 2011;82(4):404-409.
100. Hasper D, von Haehling S, Storm C, Jörres A, Schefold JC. Changes in serum creatinine in the frst 24 hours after cardiac arrest indicate prognosis: an observational cohort study. Crit Care. 2009;13(5):R168.
101. Li J, Solus J, Chen Q, et al. Role of infammation and oxidative stress in atrial fbrillation. Heart Rhythm. 2010;7(4):438-444.
102. Bakowski D, Wozakowska-Kaplon B, Opolski G. The infuence of left ventricle diastolic function on natriuretic peptides levels in patients with atrial fbrillation. Pacing Clin Electrophysiol. 2009;32(6):745-752.
103. Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fbrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012;125(13):1605-1616.
104. Conti A, Mariannini Y, Viviani G, et al. Abnormal troponin level as short-term predictor of poor outcome in acute atrial fbrillation. Am J Emerg Med. 2013;3(4)1:699-704.
105. Marcus GM, Smith LM, Ordovas K, et al. Intracardiac and extracar-diac markers of infammation during atrial fbrillation. Heart Rhythm. 2010;7(2):149-54.
106. Kryvenko V. Biomarkers of systemic infammation, oxidative stress and their interactions in patients with combined fow of chronic obstructive pulmonary disease and arterial hypertension. Georgian Med News. 2013;(216):23-28.
107. Walton KG, Pugh ND, Gelderloos P, Macrae P. Stress reduction and preventing hypertension: preliminary support for a psychoneuroendocrine mechanism. J Altern Complement Med. 1995;1(3):263-83.
108. Goodacre SW, Bradburn M, Cross E, et al. The Randomised Assessment of Treatment using Panel Assay of Cardiac Markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart. 2011;97(3):190-196.
109. Birkhahn RH, Haines E, Wen W, Reddy L, Briggs WM, Datillo PA. Estimating the clinical impact of bringing a multimarker cardiac panel to the bedside in the ED. Am J Emerg Med. 2011;29(3):304-308.
110. Takakuwa KM, Ou FS, Peterson ED, et al. The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non-ST-segment elevation acute coronary syndrome: results from CRUSADE. Clin Cardiol. 2009;32(9):498-505.